Thrombelastography‐guided blood product use before invasive procedures in cirrhosis with severe coagulopathy
Michael J.R. Desborough, Vipul Jairath – 6 November 2015
Reply
Lesley De Pietri, Marcello Bianchini, Guadalupe Garcia‐Tsao, Erica Villa – 6 November 2015
Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
Julius M. Wilder, Lennox J. Jeffers, Natarajan Ravendhran, Mitchell L. Shiffman, John Poulos, Mark S. Sulkowski, Norman Gitlin, Kimberly Workowski, Yanni Zhu, Jenny C. Yang, Phillip S. Pang, John G. McHutchison, Andrew J. Muir, Charles Howell, Kris Kowdley, Nezam Afdhal, K. Rajender Reddy – 6 November 2015 – Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon‐based treatment than patients of other races.
“Targeting” hepatitis C after liver transplantation
Maria‐Carlota Londoño, Zoe Mariño, Xavier Forns – 5 November 2015
Liver capsule: Hepatitis C virus host cell entry
Sharon E. Hopcraft, Matthew J. Evans – 4 November 2015
Liver capsule: Hepatitis C virus host cell entry
Sharon E. Hopcraft, Matthew J. Evans – 4 November 2015
An empirical broad spectrum antibiotic therapy in health‐care–associated infections improves survival in patients with cirrhosis: A randomized trial
Manuela Merli, Cristina Lucidi, Vincenza Di Gregorio, Barbara Lattanzi, Valerio Giannelli, Michela Giusto, Alessio Farcomeni, Giancarlo Ceccarelli, Marco Falcone, Oliviero Riggio, Mario Venditti – 3 November 2015 – Early diagnosis and appropriate treatment of infections in cirrhosis are crucial because of their high morbidity and mortality. Multidrug‐resistant (MDR) infections are on the increase in health care settings. Health‐care–associated (HCA) infections are still frequently treated as community‐acquired with a detrimental effect on survival.
An empirical broad spectrum antibiotic therapy in health‐care–associated infections improves survival in patients with cirrhosis: A randomized trial
Manuela Merli, Cristina Lucidi, Vincenza Di Gregorio, Barbara Lattanzi, Valerio Giannelli, Michela Giusto, Alessio Farcomeni, Giancarlo Ceccarelli, Marco Falcone, Oliviero Riggio, Mario Venditti – 3 November 2015 – Early diagnosis and appropriate treatment of infections in cirrhosis are crucial because of their high morbidity and mortality. Multidrug‐resistant (MDR) infections are on the increase in health care settings. Health‐care–associated (HCA) infections are still frequently treated as community‐acquired with a detrimental effect on survival.
The profile of platelet α‐granule released molecules affects postoperative liver regeneration
Patrick Starlinger, Stefanie Haegele, Florian Offensperger, Lukas Oehlberger, David Pereyra, Julia B Kral, Waltraud C. Schrottmaier, Sigrun Badrnya, Thomas Reiberger, Arnulf Ferlitsch, Judith Stift, Florian Luf, Christine Brostjan, Thomas Gruenberger, Alice Assinger – 3 November 2015 – Platelets promote liver regeneration through site‐specific serotonin release from dense granules, triggering proliferative signaling in hepatocytes.
Antibiotic prophylaxis in cirrhosis: Good and bad
Javier Fernández, Puneeta Tandon, Jose Mensa, Guadalupe Garcia‐Tsao – 3 November 2015 – Patients with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacterial infections that may further precipitate other liver decompensations including acute‐on‐chronic liver failure. Infections constitute the main cause of death in patients with advanced cirrhosis, and strategies to prevent them are essential.